Author: Antonio Gonçalves; Julie Bertrand; Ruian Ke; Emmanuelle Comets; Xavier de Lamballerie; Denis Malvy; Andrés Pizzorno; Olivier Terrier; Manuel Rosa Calatrava; France Mentré; Patrick Smith; Alan S Perelson; Jérémie Guedj
Title: Timing of antiviral treatment initiation is critical to reduce SARS-Cov-2 viral load Document date: 2020_4_7
ID: n6l2804j_2
Snippet: Despite the unprecedented mobilization of the clinical and scientific community, the 57 development and large scale implementation of new antiviral drugs or vaccines will take 58 months or more. To readily propose a first line of defense and combat the virus in hospitalized 59 patients, the World Health Organization relies on already existing drugs ("repurposed") that 60 are immediately available in large quantities and have a good safety profile.....
Document: Despite the unprecedented mobilization of the clinical and scientific community, the 57 development and large scale implementation of new antiviral drugs or vaccines will take 58 months or more. To readily propose a first line of defense and combat the virus in hospitalized 59 patients, the World Health Organization relies on already existing drugs ("repurposed") that 60 are immediately available in large quantities and have a good safety profile. In coordination 61 with other European institutions, France is implementing a randomized clinical trial in 62 hospitalized patients ("DisCoVery", NCT04315948) comparing the efficacy of 63 lopinavir/ritonavir ± IFN-β-1a, remdesivir and hydroxychloroquine. Given the very limited 64 knowledge of the host/pathogen interaction the clinical efficacy of treatment strategies using 65 these drugs is largely unknown and could be limited [1] . 66
Search related documents:
Co phrase search for related documents- clinical trial and good safety profile: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- clinical trial and host pathogen: 1
- clinical trial and hydroxychloroquine remdesivir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27
- clinical trial and large scale: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67
- clinical trial and large scale implementation: 1, 2
- clinical trial and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- clinical trial and safety profile: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- clinical trial and scientific clinical community: 1, 2, 3
- clinical trial and treatment strategy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- clinical trial and virus combat: 1, 2, 3
- defense line and good safety profile: 1
- defense line and host pathogen: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- defense line and host pathogen interaction: 1, 2
- defense line and large scale: 1, 2, 3, 4
- defense line and lopinavir ritonavir: 1
- defense line and safety profile: 1
- defense line and treatment strategy: 1
- defense line and virus combat: 1
- good safety profile and large scale: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date